- About the Study
- The goal of this study is to test if GS-5245 is safe and effective for the treatment of COVID-19 in participants who have a standard risk of developing severe illness.
- What does the study involve?
- Participants will receive a tablet (GS-5245 350 mg or a placebo) administered orally without regard to food twice daily for 5 days.
- Who can participate?
- Participants must be at between 12 and 64 years old, diagnosed with Covid 19 within the last 72 hours, with symptoms.
- Where is the study taking place?
- The study is being conducted at our Hollywood, Boynton, and Weston offices.
- Is compensation provided?
- Yes, you will be compensated for your participation. Travel reimbursement and meals are not provided.